



31 August 2020

Sydney, Australia

## Nyrada Board Changes

- Nyrada founder and seasoned biotech entrepreneur, Dr Ian Dixon joins the Board as non-executive director
- Dr Dixon's appointment brings more than 20 years' Australian biotech experience, including from Altnia and listed companies Exopharm and Cynata
- Dr Graham Kelly steps down from his role as non-executive director on the Board to focus on CEO role at Noxopharm

**Nyrada Inc** (ASX: NYR), the drug discovery and development company, today announces Ian Dixon, PhD, MBA, MAICD will join the Board of Nyrada Inc. In addition, Dr Graham Kelly will step down from the Board to focus on his role as Noxopharm CEO and Managing Director but will remain involved in Nyrada as a consultant. The changes are effective immediately after the approval and lodgement of the audited Financial Statements or Audited Annual Report with the ASX. Upon this event occurring, the Company will lodge Appendix 3x and Appendix 3z for the respective directors.

"We are thrilled to welcome Ian to Nyrada's Board. Back in 2014, Ian was inspired to solve one of pharma's biggest challenges for treating high cholesterol: how to make a cost-competitive and convenient small molecule PCSK9 inhibitor to improve patient compliance. His expertise and determination led to the foundation of our Cholesterol Lowering program. This program is going from strength to strength with very encouraging preclinical results already and we are delighted he will help us advance the program," said John Moore, Nyrada Chairman.

"Dr Kelly has been involved with Nyrada since its inception in 2017. His vision and expertise have been instrumental in establishing the Company and assembling a world-class Board to drive its success. We thank him for diligence and commitment over the years and wish him all the best as he focuses on Noxopharm," Moore concluded.

Dr Dixon is a seasoned biotechnology entrepreneur with more than 20 years' experience in the Australian sector. Together with Dr Kelly, he founded Nyrada Inc. Ian is a co-inventor of the technology behind its Cholesterol Lowering Program, giving him deep expertise in the development of PCSK9 inhibitors. Dr Dixon is also Chairman and founder of Altnia Group, a privately held Australian biotechnology incubator and life sciences R&D company which has a 9.07% holding in Nyrada Inc and a further 5,999,400 Performance Shares.

Currently Founder and Managing Director of exosome medicine company, Exopharm (ASX: EX1), Dr Dixon also serves as a part-time executive director of Medigard Ltd (ASX: MGZ). In addition, Dr Dixon co-founded Cynata Inc. – now a subsidiary of Australian listed biotechnology company, Cynata Therapeutics Ltd (ASX: CYP). Until recently he was a non-executive director of Noxopharm Ltd (ASX: NOX), Nyrada's largest shareholder. Dr Dixon was a director of Cell Therapies Pty Ltd. Dr Dixon has a PhD in biomedical engineering from Monash University, an MBA from Swinburne University and professional engineering qualifications.



## **About Nyrada Inc**

Nyrada is a preclinical stage, drug discovery, and development company, specialising in novel small molecule drugs to treat cardiovascular, neurological, and inflammatory/autoimmune diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol-lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, USA, and the liability of its stockholders is limited.

-ENDS-

*Authorised by Mr. John Moore, Non-Executive Chairman, on behalf of the Board*

[www.nyrada.com](http://www.nyrada.com)

### **Investor & Corporate Enquiries:**

Prue Kelly  
T: 0459 022 445  
E: [info@nyrada.com](mailto:info@nyrada.com)

### **Company Secretary:**

David Franks  
T: 02 8072 1400  
E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

### **Media Enquiries:**

Catherine Strong  
Citadel-MAGNUS  
T: 02 8234 0111  
E: [cstrong@citadelmagnus.com](mailto:cstrong@citadelmagnus.com)

### **Forward-Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.